文献速递腹部泌尿生殖CT

肾上腺腺瘤的肝脏脂肪分数与脂质含量:非增强CT的启示

Hepatic fat fraction and lipid content of adrenal adenomas: insights from unenhanced CT.
PubMed 文献 · Abdom Radiol (NY) · 2025-11-24

本回顾性研究纳入2023年9月至2025年6月间经非增强CT诊断的176例患者(211个肾上腺腺瘤),评估肝脏脂肪分数(HFF)与肾上腺腺瘤脂质含量的关系。结果显示肾上腺腺瘤衰减值与肝脏衰减值或HFF均无显著相关性(p=.519和p=.566),腺瘤直径与HFF呈弱负相关(r=-.137,95%CI:-0.25至-0.02;p=.046)。结论认为肾上腺腺瘤与代谢功能障碍相关脂肪性肝病(MASLD)无显著关系,肝脏脂肪变性与肾上腺腺瘤脂质含量似乎是独立过程。

要点

  • 肾上腺腺瘤衰减值与肝脏衰减值或HFF均无显著相关性(p=.519和p=.566)。
  • 腺瘤直径与HFF呈弱负相关(r=-.137,95%CI:-0.25至-0.02;p=.046)。
  • 肝脏脂肪变性与FIB-4指数之间未发现关联。

核心结论

  • 本研究未证明肾上腺腺瘤与MASLD之间存在显著关系,肝脏脂肪变性与肾上腺腺瘤脂质含量似乎代表独立过程。

研究设计与样本

  • 回顾性研究,纳入2023年9月至2025年6月间经非增强CT诊断的176例患者(211个肾上腺腺瘤);肾上腺腺瘤定义为衰减值≤10 HU的病灶或>10 HU但随访影像稳定的病灶;肝脏衰减值测量三个区域,HFF计算公式为脂肪分数=-0.58×CT值(HU)+38.2;患者分为四个脂肪变性组(正常、轻度、中度、重度);计算FIB-4指数评估肝纤维化。

诊断标准与关键数值

  • 肾上腺腺瘤定义:衰减值≤10 HU,或>10 HU但随访影像稳定。
  • HFF计算公式:脂肪分数=-0.58×CT值(HU)+38.2。
  • 患者按脂肪变性程度分为正常、轻度、中度、重度四组。
  • 肾上腺腺瘤衰减值与肝脏衰减值无显著相关性(p=.519),与HFF无显著相关性(p=.566)。
  • 腺瘤直径与HFF呈弱负相关(r=-.137,95%CI:-0.25至-0.02;p=.046)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Adrenal incidentalomas (AI) are increasingly detected with the widespread use of abdominal computed tomography (CT). Although a relationship between AI, metabolic syndrome, and metabolic dysfunction-associated steatotic liver disease (MASLD) has been suggested, the evidence remains limited.

PURPOSE: To investigate the relationship between hepatic fat fraction (HFF) and lipid content of adrenal adenomas using unenhanced CT.

METHODS: This retrospective study included 176 patients (211 adrenal adenomas) diagnosed on unenhanced CT between September 2023 and June 2025. Adrenal adenomas were defined as lesions with attenuation ≤ 10 Hounsfield units (HU) or > 10 HU with stability on follow-up imaging. Hepatic attenuation was measured in three regions, and HFF was calculated with the formula: Fat fraction = - 0.58 × CT(HU) + 38.2. Patients were classified into four steatosis groups (normal, mild, moderate, severe). The fibrosis-4 index (FIB-4) was calculated to assess liver fibrosis. Statistical analyses included the Kruskal-Wallis H test for continuous variables, Chi-square test for categorical comparisons, and Pearson's correlation for associations.

RESULTS: The study population consisted of 59% females and 41% males, with a mean age of 59 years. Most adenomas were nonfunctioning (94%). Adenoma attenuation ranged from - 89 to + 28 HU. No significant correlation was found between adrenal adenoma attenuation and liver attenuation or HFF (p = .519 and p = .566, respectively). A weak negative correlation was observed between adenoma diameter and HFF (r = -.137, 95% CI: - 0.25 - - 0.02; p = .046). No association was found between hepatic steatosis and FIB-4 index.

CONCLUSION: This study did not demonstrate a significant relationship between adrenal adenomas and MASLD. Hepatic steatosis and lipid content of adrenal adenomas appear to represent independent processes.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Konukoglu O, Kaya M, Cindemir E, et al. Hepatic fat fraction and lipid content of adrenal adenomas: insights from unenhanced CT. Abdom Radiol (NY). 2025. PMID: 41284029. doi:10.1007/s00261-025-05310-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。